Earnings summaries and quarterly performance for WINDTREE THERAPEUTICS INC /DE/.
Executive leadership at WINDTREE THERAPEUTICS INC /DE/.
Board of directors at WINDTREE THERAPEUTICS INC /DE/.
Research analysts who have asked questions during WINDTREE THERAPEUTICS INC /DE/ earnings calls.
Recent press releases and 8-K filings for WINT.
Windtree Therapeutics Sells Cardiovascular Drug Candidates
WINT
M&A
New Projects/Investments
- Windtree Therapeutics, Inc. (WINT) has sold its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC (SPH).
- Windtree is entitled to 20% of any future proceeds received by SPH, which includes milestone payments, royalty payments, or global commercial net revenues.
- A contingent payment of $700,000 will be made to Windtree if SPH completes a financing round of at least $10,000,000 to fund the development of these assets.
- As part of the agreement, Windtree will transfer certain cardiovascular development payables to SPH, eliminating its obligation to fund the development of these drug candidates.
Dec 23, 2025, 2:00 PM
Windtree Therapeutics Issues Convertible Notes for Acquisition and General Corporate Purposes
WINT
Debt Issuance
M&A
Convertible Preferred Issuance
- Windtree Therapeutics, Inc. (WINT) issued $857,142.86 in senior convertible promissory notes due November 26, 2026, bearing 10% annual interest.
- The company intends to use $450,000 of the proceeds as an advance to CommLoan Inc. for a potential acquisition and retain $150,000 for general corporate purposes.
- The notes are convertible into common stock at the holder's option, with the conversion price set at 90% of the lowest sale price over the 20 consecutive trading days preceding conversion.
- Mandatory prepayment at a 115% premium is required if the company completes a qualified equity financing of $1 million or more or receives 25% of gross proceeds from a specific Common Stock Purchase Agreement.
- Holders have "Rollover Rights" to apply outstanding principal and interest as purchase consideration for future equity, equity-linked, or debt securities offerings, at 80% of the cash purchase price paid to other investors in such transactions.
Dec 2, 2025, 9:31 PM
Fintool News
In-depth analysis and coverage of WINDTREE THERAPEUTICS INC /DE/.
Quarterly earnings call transcripts for WINDTREE THERAPEUTICS INC /DE/.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more